ClinicalTrials.gg
RecruitingNCT06726200Updated Jun 2, 2026

A Clinical Trial Comparing Buprenorphine Formulations for High Potency Synthetic Opioid Use

An Early Phase 1 interventional study of Buprenorphine + naloxone (Suboxone) and Buprenorphine Injection in Opioid Use Disorder, sponsored by Rachel R. Luba. Recruiting at 1 site in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-06-02.

Sponsored by Rachel R. Luba · Early Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Feb 2026; still recruiting 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Early Phase 1
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 173 studies testing buprenorphine in Opioid-Related Disorders — 19 open to participants now, 21 under way, 5 of them phase 3. Buprenorphine · Opioid-Related Disorders.

Planned enrollment
54th of 172
60 · median 19
Started
2026
with 6 others
Phase 1
20 of 173
1 open now
Primary completion
2029-01
later than 17 of 20 live
Registered
164th of 173
by date

Among the 173 studies testing buprenorphine in Opioid-Related Disorders, this one is the 54th largest by planned enrollment of the 172 interventional ones that give a count, is one of 7 that started in 2026, is one of 20 in phase 1, reaches primary completion later than 17 of the 20 other live ones, and was the 164th registered.

Opioid-Related Disorders

1,476 studies on the registry are indexed under Opioid-Related Disorders; 293 are open to participants now.

Browse Opioid-Related Disorders studies →

Open to participants now

19 of the 173 studies testing buprenorphine in Opioid-Related Disorders are open now, in 2 countries. Recruiting first, the newest first:

13 more — sign in →

By country, each count listing its studies:

All 19 open studies →

About buprenorphine

Buprenorphine: first FDA approval 1981 (BUPRENEX), first EMA approval 2006. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 213 Opioid-Related Disorders studies recruiting now, 123 (58%) set no upper age limit and 76 (36%) stop at 75 or younger; 14 take children under 18; 53 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 173 studies testing buprenorphine in Opioid-Related Disorders, or all of them as a file.
02

Study summary

The goal of this clinical trial is to compare buprenorphine formulations (sublingual buprenorphine versus long-acting injectable buprenorphine) for treating opioid use disorder among individuals who use fentanyl and/or other high potency synthetic opioids. Individuals aged 18-65 will be eligible for enrollment. The main questions it aims to answer are:

Are there differences in frequency of drug use after individuals start treatment with sublingual buprenorphine compared to injectable buprenorphine?

Are there differences in rates of sustained relapse after individuals start treatment with sublingual buprenorphine compared to injectable buprenorphine?

Investigators also seek to understand and explore:

How factors like body fat, body weight, and quantity of fentanyl use before treatment influence treatment outcomes.

How blood levels of buprenorphine and its metabolite norbuprenorphine early on in treatment may influence treatment outcomes.

How factors like craving and opioid withdrawal symptoms influence treatment outcomes.

Participants will:

Complete a brief overnight hospital stay in an inpatient research unit. This hospital stay will enable participants to start treatment with either sublingual buprenorphine or injectable buprenorphine.

Provide blood and urine samples while on the inpatient unit and at follow up.

Complete in-person follow up visits at 1-, 2-, 3- and 4-weeks after leaving the hospital to measure drug use, craving, withdrawal, quality of life, and physical health.

03

Conditions studied

  • Opioid Use Disorder
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Aged 18 to 65
  • Voluntarily seeking treatment for opioid use disorder (OUD)
  • Consistent use of fentanyl or other high potency synthetic opioids
  • Meets criteria for OUD with at least moderate severity
  • Able to provide written in English and willing to comply with study procedures

Exclusion criteria

Exclusion Criteria:

  • Meets criteria for another substance use disorder as the primary diagnosis
  • Has an active, unmanaged psychiatric condition that would make participation hazardous (e.g., acute, psychosis, current suicidality, current manic episode)
  • Has an active, unmanaged medical condition that would make participation hazardous or preclude use of buprenorphine or ancillary medications for withdrawal (e.g., unmanaged hypertension, unmanaged diabetes, abnormality on , acute hepatitis)
  • Buprenorphine or methadone treatment in the past 30 days
  • Known allergy, or intolerance to buprenorphine
  • Pregnancy, lactation, or unwillingness to use adequate methods
  • Current physiological dependence on sedative-hypnotics or alcohol that would require medically supervised detoxification
  • Liver function tests > 2x the
  • Use of medications or herbal products with known inhibition or induction properties in the past 30 days
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Early Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    Injectable Buprenorphine

    Long-Acting Injectable Buprenorphine administered after participants receive and tolerate a single 4/1 mg sublingual buprenorphine/naloxone dose

    Drug: Buprenorphine Injection

  • Active comparator
    Sublingual Buprenorphine/Naloxone

    Titration onto sublingual buprenorphine/naloxone (standard of care)

    Drug: Buprenorphine + naloxone (Suboxone)

Interventions

  • DrugBuprenorphine + naloxone (Suboxone)

    Drug page: BuprenorphineStudies of BuprenorphineBuprenorphine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Participants randomized to sublingual buprenorphine naloxone will initiate treatment based on clinical guidelines/standard of care

  • DrugBuprenorphineStudies of BuprenorphineBuprenorphine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Participants randomized to injectable buprenorphine naloxone will receive a 300mg injection after receiving/tolerating a single 4/1 mg sublingual buprenorphine/naloxone dose

06

What researchers measure

Primary outcomes

  1. Percentage of Days Abstinent from Opioids

    Abstinence from Opioids (% days abstinent; continuous; longitudinal) during each week of the 4 week follow up period measured via the timeline follow back.

    Time frame: 4 week follow up period

  2. Sustained Relapse

    Sustained relapse during the 4 week follow up period (binary), defined as 5 consecutive days of illicit opioid use reported on the timeline follow back at any point during the 4 week follow up period.

    Time frame: 4 week follow up period

Secondary outcomes

  1. Time to Peak Clinical Opiate Withdrawal Scale (COWS) score

    The time to peak Clinical Opiate Withdrawal Scale (COWS) score during the induction period (time-to-event/survival). The COWS ranges from 0-48 with higher scores indicating more severe opioid withdrawal symptoms.

    Time frame: During the inpatient induction period (approximately 1 overnight stay)

  2. Peak Clinical Opiate Withdrawal Scale (COWS) score

    The peak Clinical Opiate Withdrawal Scale (COWS) score during the induction period (continuous). The COWS ranges from 0-48 with higher scores indicating more severe opioid withdrawal symptoms.

    Time frame: During the inpatient induction period (approximately 1 overnight stay)

  3. Dropout during induction

    Dropout during the induction period (binary)

    Time frame: During the inpatient induction period (approximately 1 overnight stay)

Other outcomes

  1. Exploratory Outcome 1: Craving

    Craving as reported on the Opioid Craving Visual Analog Scale OC-VAS (longitudinal; continuous) during induction and follow up. The OC-VAS ranges from 0-100mm with higher ratings indicating more intense/severe craving.

    Time frame: Induction Period (Overnight Inpatient Stay) and 4-week follow up period

  2. Exploratory Outcome 2: Clinical Opiate Withdrawal Scale (COWS) Score

    Opioid Withdrawal Symptoms as reported on the Clinical Opiate Withdrawal Scale (COWS; longitudinal; continuous) during induction and follow up. The COWS ranges from 0-48 with higher scores indicating more severe opioid withdrawal symptoms.

    Time frame: Induction Period (Overnight Inpatient Stay) and 4-week follow up period

  3. Exploratory Outcome 3: Time to first use of illicit opioids

    Time to first use of illicit opioids during the 4-week follow up period (time-to-event/survival)

    Time frame: 4-week follow up period

07

Study locations

1 of 1 sites recruiting
  • Substance Treatment and Research Service
    New York, New York 10019, United States
    Recruiting
08

References and documents

Individual participant data

Plan to share: Yes — According to NIDA's policy for data management and sharing, de-identified data will be deposited into the NAHDAP repository.

Time frame: De-identified data will be made available no later than when the primary outcome paper is published or when the award ends. The data will be stored in the repository for at least 10 years after the funding period ends.

Access criteria: Once released to the repository, the investigator will not control data access.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2026 (actual). Primary completion is estimated for Jan 2029, 34 months after the start.

Of 55 non-industry phase 1 interventional studies under Opioid-Related Disorders, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 47. This study's planned 34 months is above that.

Counting every sponsor, half of 79 studies reached it within 19 months; a quarter within 9 and three quarters within 33.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 3, 2024
First posted
Dec 10, 2024
StartActual
Feb 25, 2026
Primary completionEst.
Jan 15, 2029
CompletionEst.
Jan 15, 2029
Last update
Jun 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 2, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06726200
Lead sponsor
Rachel R. Luba
Responsible party
Rachel R. Luba (Associate Research Scientist, Columbia University) — Sponsor-investigator
First posted
Dec 10, 2024
Start date
Feb 25, 2026
Primary completion
Jan 15, 2029 (estimated)
Completion
Jan 15, 2029 (estimated)
Last update
Jun 2, 2026

Study contacts

Rachel Luba, PhD
Contact
RRL2117@CUMC.Columbia.edu
646-774-8189
John Mariani, MD
Contact
jm2330@cumc.columbia.edu
212-923-3031

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Buprenorphine

Start the discussion